Inhibitors of MEK, such as binimetinib, have proven to be an effective treatment for patients with metastatic melanoma.1 However, serous retinopathy is a common complication of binimetinib.1–4 Binimetinib-associated serous retinopathy develops in up to 77% of metastatic cutaneous melanoma patients and in 60% of metastatic uveal melanoma patients.2 Although the central retina (macula) was affected in most patients, only 22% of all patients in our previous clinical study developed visual complaints. The gene discussed is MAP2K7; the disease is metastatic melanoma.